Immunology Department Metrics

CLINICAL TRIAL 19662
Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer
Condition: Gynecological Tumor
Intervention: Atezolizumab (Tecentriq)

CLINICAL TRIAL 19724
Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 20042
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients with MDS and Secondary AML
Condition: Malignant Hematology
Intervention: Cladribine (); Cytarabine (Cytosine Arabinoside); Daunomycin (daunorubicin); G-CSF (); GDC-0199 (Venetoclax); Idarubicin (); Novantrone (mitoxantrone); Venetoclax (); Zevados (Idarubicin); daunorubicin (); mitoxantrone ()

CLINICAL TRIAL 20313
Neoadjuvant Immunotherapy with Intratumoral Tavokinogene Telseplasmid (Tavo) plus Electroporation in Combination with Intravenous Nivolumab in Patients with Operable Locally- Regionally Advanced Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); Tavo-EP ()

CLINICAL TRIAL 20487
Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease
Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab (); Radiotherapy (); Trastuzumab (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); Ipilimumab (); Nivolumab (Opdivo); Proleukin (Interleukin-2); Yervoy (Ipilimumab)

CLINICAL TRIAL 20578
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Condition: Malignant Hematology
Intervention: ALLO-501A (); ALLO-647 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 20737
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release
Condition: Malignant Hematology
Intervention: cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); lisocabtagene maraleucel ()

CLINICAL TRIAL 20877
A Phase Ib /Randomized Phase III Trial of Patients with Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation with Either Orca-T, a T-cell-Depleted Graft with Additional Infusion of Conventional T cells and Regulatory T cells, or Standard-of-Care Allogeneic Graft
Condition: Malignant Hematology
Intervention: FK506 (Tacrolimus); Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus (); Tacrolimus ()

CLINICAL TRIAL 20778
Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym M (ALVR-105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant
Condition: Malignant Hematology
Intervention: Viralym-M/Placebo ()

CLINICAL TRIAL 20794
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: Safety and Biomarker Analysis
Condition: Cutaneous
Intervention: Cemiplimab (); REGN2810 (Cemiplimab)

CLINICAL TRIAL 20923
A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Condition: Malignant Hematology
Intervention: Fedratinib ()

CLINICAL TRIAL 20899
Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases
Condition: Breast
Intervention: Abemaciclib (); Endocrine Therapy (); LY2835219 (Abemaciclib); Radiotherapy ()

CLINICAL TRIAL 21023
Open Label, Multicenter Phase II Study of the C5A- Antibody IFX-1 Alone or IFX-1 + Pembrolizumab in Patients with PD-1- or PD-L1-Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
Condition: Cutaneous
Intervention: IFX-1 (); Not Applicable (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20955
A Phase II Study of Binimetinib plus Belinostat for Subjects with Metastatic Uveal Melanoma
Condition: Cutaneous
Intervention: Belinostat (); Binimetinib (); PXD101 (Belinostat)

CLINICAL TRIAL 21080
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors (DRAGON)
Condition: Multiple
Intervention: Atezolizumab (Tecentriq); BMS-936558 (Nivolumab); Cemiplimab (); Nivolumab (Opdivo); Pembrolizumab (Keytruda); REGN2810 (Cemiplimab); SRK-181 ()

CLINICAL TRIAL 21209
A Phase 1, Open Label, Multiple-Ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Efficacy of KD033 In Subjects With Metastatic Or Locally Advanced Solid Tumors
Condition: Multiple
Intervention: KD033 (); Not Applicable ()

CLINICAL TRIAL 21239
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); Sargramostim (); Yervoy (Ipilimumab)

CLINICAL TRIAL 21344
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Melanoma (Morpheus-Melanoma)
Condition: Cutaneous
Intervention: Atezolizumab (Tecentriq); BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); RO7247669 (); Tiragolumab (); Yervoy (Ipilimumab)

CLINICAL TRIAL 21366
Administration of HIV-specific T Cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Carmustine (); Cytarabine (Cytosine Arabinoside); Melphalan (); etoposide ()

CLINICAL TRIAL 21426
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Posoleucel (ALVR105, Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 21448
Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer
Condition: Breast
Intervention:

CLINICAL TRIAL 21452
Evaluating Gut Microbiome As A Biomarker Of Pathological Complete Response In Patients With Early Triple Negative Breast Cancer - A Pilot Study (TCC)
Condition: Breast
Intervention:

CLINICAL TRIAL 21525
A Feasibility Study of Genomically Guided Radiation Dose Personalization in the Management of Locally Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Radiotherapy ()

CLINICAL TRIAL 21606
Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients with Respiratory Viral Infections After Hematopoietic Cell Transplant
Condition: Malignant Hematology
Intervention: ALVR106 (); Diphenhydramine (); acetaminophen ()

CLINICAL TRIAL 21623
A Phase 1/2 Study of bbT369, a Dual Targeting CAR T cell Drug Product with a Gene Edit, in Relapsed and/or Refractory B cell Non-Hodgkin s Lymphoma
Condition: Immunotherapy
Intervention: Lymphodepletion (); bbT369 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 21696
A Phase 1/2 Dose-Escalation and Dose-Expansion of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T cells (WU-CART-007) in Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia /Lymphoblastic Lymphoma (T-ALL)/Lymphoblastic Lymphoma (LBL)
Condition: Malignant Hematology
Intervention: Cladribine (); WU-CART-007 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 21741
A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination with AGEN1181, an Fc-Enqineered Anti-CTLA-4 Monoclonal Antibody, in Patients with Advanced Cancer
Condition: Cutaneous
Intervention: AGEN1181 (); AGEN2373 ()

CLINICAL TRIAL 21757
Phase II Study of Genomically Guided Radiation Dose Personalization in the Management of Triple Negative Breast Cancer
Condition: Breast
Intervention: Radiotherapy ()

CLINICAL TRIAL 21894
Phase 1 Clinical Trial of lntravesical Adoptive Cell Therapy {ACT) with Tumor Infiltrating Lymphocytes (TIL) for Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer {NMIBC)
Condition: Genitourinary
Intervention:

CLINICAL TRIAL 21913
A Phase 3 Study of CG0070 In Patients with Non- Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Condition: Genitourinary
Intervention: CG0070 (); DDM ()

CLINICAL TRIAL 22009
CTNO155X2101: An Open-Label, Multi-Center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients with Advanced Solid Tumors
Condition: Cutaneous
Intervention: TNO155 ()

CLINICAL TRIAL 22539
Request for Single Patient Emergency Access Use of Axicabtagene Ciloleucel
Condition: Malignant Hematology
Intervention:

• 2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
  Sponsor: Nat Institutes of Health
  PI (Contact):Wright, K.,PI (MPI):Monteiro, A.
• Augmenting T Cell Trafficking and Functionality through Novel Combinations of Epigenetic Agents and PD-1 Blockade
  Sponsor: Nat Institutes of Health
  PI:Beg, A.
• Regulation of dendritic cell function and tumor immunity by TIM-3
  Sponsor: Nat Institutes of Health
  PI:Ruffell, B.
• Reprogramming Transmembrane ubiquitin Ligases To Control Cell Surface Receptor Landscapes.
  Sponsor: Rita Allen Foundation
  PI:Luca, V.
• Functional reprogramming of tumor-MDSC through antibody-based therapies Targeting Notch Ligands
  Sponsor: Nat Institutes of Health
  PI:Rodriguez, P.
• Imaging Acidosis and Immune Therapy in PDAC
  Sponsor: Nat Institutes of Health
  PI (Contact):Pilon-Thomas, S.,PI:Ibrahim Hashim, A.
• Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering
  Sponsor: Nat Institutes of Health
  PI:Luca, V.
• Targetable Epidgenetic Mechanism Driving Cutaneous T Cell Lymphoma
  Sponsor: Nat Institutes of Health
  PI (Contact):Conejo-Garcia, J.,PI:Pinilla, J.,PI:Sokol, L.
• Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on γδ T cells, in the bone microenvironment.
  Sponsor: Nat Institutes of Health
  PI:Abate Daga, D.
• Determine the effects of the TP-0184 and its derivatives (second generation) on myeloid-derived suppressor cell (MDSC)-mediated suppressive functions and improve the local bone marrow (BM) microenvironment in patients with MDS
  Sponsor: Sumitomo Pharma Oncology
  PI (Contact):Wright, K.,PI:Eksioglu, E.
• Intellia Research Collaboration - Project 1: Advancing Neoantigen-Specific T Cells
  Sponsor: Intellia Therapeutics
  PI:Pilon-Thomas, S.,CO-PI:Abate Daga, D.
• A Phase II Biomarker Trial of CC-122 in Combination with Nivolumab in Advanced Melanoma
  Sponsor: Celgene Corp.
  PI:Pilon-Thomas, S.
• Notch signaling boosts T cell-based immunotherapy
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Rodriguez, P.,CO-PI:Luca, V.
• Myst/Turnstone– Moffitt Collaboration - Melanoma & Colorectal
  Sponsor: Turnstone Biologics
  PI (Contact):Pilon-Thomas, S.,CO-PI:Beatty, M.,CO-PI:Fleming, J.,CO-PI:Teer, J.,CO-PI:Mulé, J.
• NSG Mouse Models to Evaluate the Efficacy of TIL
  Sponsor: Iovance Biotherapeutics
  PI:Pilon-Thomas, S.
• Utilize patient-derived PCa explants to define the mechanism of RT-induced changes in Tumor Microenvironment to promote response to immune-modulatory therapy
  Sponsor: Moffitt Cancer Center
  PI:Rodriguez, P.
• Role of Bcl11b in CD4+ T Cells and Innate Lymphoid Cells
  Sponsor: Nat Institutes of Health
  PI:Avram, D.
• High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase
  Sponsor: Nat Institutes of Health
  PI (MPI):Avram, D.
• Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury
  Sponsor: Nat Institutes of Health
  PI:Avram, D.
• Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds
  Sponsor: Nat Institutes of Health
  PI:Rodriguez, P.
• Plant-derived extracts regulate immunosuppressive myelopoiesis in Breast cancer patients
  Sponsor: Nat Institutes of Health
  PI:Rodriguez, P.
• Mechanisms of functional heterogeneity of tumor associated macrophages in glioblastoma
  Sponsor: Ivy (Ben & Catherine) Fdtn
  PI:Veglia, F.
• Engineering Bispecific Nanobodies for Detection of Breast Cancer Nodal Metastasis
  Sponsor: US Army
  PI:Luca, V.
• Institutional Research Grant - Moffitt Cancer Center
  Sponsor: Amer Cancer Society
  PI:Wright, K.
• Preclinical studies of MEM-288
  Sponsor: Memgen
  PI:Beg, A.
• Platinum-induced lipid reprogramming and tumor immune microenvironment in SCLC
  Sponsor: Nat Institutes of Health
  PI:Avram, D.
• Study of Anti-Tumor Immunity and Tissue Resident Memory Cell Development by NKG2D and Ribosomal Protein S6 Signaling in T cells
  Sponsor: Nat Institutes of Health
  PI:Guevara, J.
• Tech Transfer support and clinical protocol development for the use of TIL in patients with melanoma
  Sponsor: Turnstone Biologics
  PI:Pilon-Thomas, S.,CO-PI:Mulé, J.
• Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering
  Sponsor: Nat Institutes of Health
  PI (MPI):Luca, V.
• Development of Adoptive T-Cell Therapy in Bladder Cancer Incorporating Patient-Specific Tumor Microenvironment
  Sponsor: US Army
  PI:Pilon-Thomas, S.
• Structure-guided engineering of LAG3 immunomodulatory function
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Luca, V.
• Targeting ENPP1 to promote immunity during PARP inhibition in TNBC
  Sponsor: US Army
  PI:Ruffell, B.
• Targeting ENPP1 to promote immunity during PARP inhibition in TNBC
  Sponsor: US Army
  PI:Luca, V.
• Transdermal Alkalinization Treatment as an Adjunct in Melanoma Therapy
  Sponsor: Dyve Biosciences
  PI:Pilon-Thomas, S.,CO-PI:Gillies, R.
• Tissue-Anchored vs. Circulating Constructs for Immunometabolic Resolution of Psoriasis
  Sponsor: Nat Institutes of Health
  PI (MPI):Avram, D.
• Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors
  Sponsor: Nat Institutes of Health
  PI:Rodriguez, P.
• The Role of Hypoxia on Tumor Infiltrating Lymphocytes (TIL) from Renal Cell Carcinoma (RCC)
  Sponsor: US Army
  PI (Contact):Pilon-Thomas, S.,CO-PI:Chahoud, J.
• Defining Tumor Infiltrating B Cells and Their Role in the Modulation of TIL Immunotherapy
  Sponsor: The Mark Foundation for Cancer Research
  PI:Pilon-Thomas, S.,CO-PI:Abate Daga, D.
• Targeting dendritic cells to improve cancer immunotherapy
  Sponsor: Cancer Research Institute
  PI:Ruffell, B.
• Generation and characterization of CD40L variants with enhanced potency
  Sponsor: Moffitt Fdtn
  PI:Luca, V.
• Evaluation of Novel CD40L molecules
  Sponsor: Moffitt Fdtn
  PI:Abate Daga, D.
• KIR2DL2 Immune Checkpoint as Modulator of T-Cell Effector Function
  Sponsor: Nat Institutes of Health
  PI:Abate Daga, D.
• Improving melanoma immunotherapy through connections of TLSs, TIL, STING, and MARCO
  Sponsor: Adelson (Miriam & Sheldon) Medical Res Fdtn
  PI:Mulé, J.
• Mitochondrial stress-related proteins regulate myeloid subsets in lung and melanoma tumors
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Rodriguez, P.

• Frieling JS, Tordesillas L, Bustos XE, Ramello MC, Bishop RT, Cianne JE, Snedal SA, Li T, Lo CH, de la Iglesia J, Roselli E, Benzaïd I, Wang X, Kim Y, Lynch CC, Abate-Daga D. γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer. Sci Adv. 2023 May.9(18):eadf0108. Pubmedid: 37134157. Pmcid: PMC10156127.
• Bracho-Sanchez E, Rocha FG, Bedingfield SK, Partain BD, Macias SL, Brusko MA, Colazo JM, Fettis MM, Farhadi SA, Helm EY, Koenders K, Kwiatkowski AJ, Restuccia A, Morales BS, Wanchoo A, Avram D, Allen KD, Duvall CL, Wallet SM, Hudalla GA, Keselowsky BG. Suppression of local inflammation via galectin-anchored indoleamine 2,3-dioxygenase. Nat Biomed Eng. 2023 May. Pubmedid: 37127708.
• Hänggi K, Ruffell B. Cell death, therapeutics, and the immune response in cancer. Trends Cancer. 2023 May.9(5):381-396. Pubmedid: 36841748. Pmcid: PMC10121860.
• Chakiryan NH, Kim Y, Berglund A, Chang A, Kimmel GJ, Hajiran A, Nguyen J, Moran-Segura C, Saeed-Vafa D, Katende EN, Lopez-Blanco N, Chahoud J, Rappold P, Spiess PE, Fournier M, Jeong D, Wang L, Teer JK, Dhillon J, Kuo F, Hakimi AA, Altrock PM, Mulé JJ, Manley BJ. Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma. J Immunother Cancer. 2023 Apr.11(4). Pubmedid: 37185232. Pmcid: PMC10151991.
• Helm EY, Zelenka T, Cismasiu VB, Islam S, Silvane L, Zitti B, Holmes TD, Drashansky TT, Kwiatkowski AJ, Tao C, Dean J, Obermayer AN, Chen X, Keselowsky BG, Zhang W, Huo Z, Zhou L, Sheridan BS, Conejo-Garcia JR, Shaw TI, Bryceson YT, Avram D. Bcl11b sustains multipotency and restricts effector programs of intestinal-resident memory CD8+ T cells. Sci Immunol. 2023 Apr.8(82):eabn0484. Pubmedid: 37115913.
• Trinh T, Adams WA, Calescibetta A, Tu N, Dalton R, So T, Wei M, Ward G, Kostenko E, Christiansen S, Cen L, McLemore A, Reed K, Whiting J, Gilvary D, Blanco NL, Segura CM, Nguyen J, Kandell W, Chen X, Cheng P, Wright GM, Cress WD, Liu J, Wright KL, Wei S, Eksioglu EA. CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies. iScience. 2023 Apr.26(4):106443. Pubmedid: 37070068. Pmcid: PMC10105289.
• Zheng H, Yu X, Ibrahim ML, Foresman D, Xie M, Johnson JO, Boyle TA, Ruffell B, Perez BA, Antonia SJ, Ready N, Saltos AN, Cantwell MJ, Beg AA. Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity. Cancer Immunol Res. 2023 Apr.11(4):466-485. Pubmedid: 36757308. Pmcid: PMC10165690.
• Potez M, Snedal S, She C, Kim J, Thorner K, Tran TH, Ramello MC, Abate-Daga D, Liu JKC. Use of phage display biopanning as a tool to design CAR-T cells against glioma stem cells. Front Oncol. 2023 Mar.13:1124272. Pubmedid: 37035164. Pmcid: PMC10080078.
• Obermayer A, Chang D, Nobles G, Teng M, Tan AC, Wang X, Eschrich S, Rodriguez P, Grass GD, Meshinchi S, Tarhini A, Chen DT, Shaw T. DRPPM-PATH-SURVEIOR: Plug-and-Play Survival Analysis of Pathway-level Signatures and Immune Components. Res Sq. 2023 Mar. Pubmedid: 36993526. Pmcid: PMC10055629.
• Garg SK, Sun J, Kim Y, Whiting J, Sarnaik A, Conejo-Garcia JR, Phelps M, Weber JS, Mulé JJ, Markowitz J. Dichotomous Nitric Oxide-Dependent Post-Translational Modifications of STAT1 Are Associated with Ipilimumab Benefits in Melanoma. Cancers (Basel). 2023 Mar.15(6). Pubmedid: 36980641. Pmcid: PMC10046641.
• Falahat R, Berglund A, Perez-Villarroel P, Putney RM, Hamaidi I, Kim S, Pilon-Thomas S, Barber GN, Mulé JJ. Epigenetic state determines the in vivo efficacy of STING agonist therapy. Nat Commun. 2023 Mar.14(1):1573. Pubmedid: 36949064. Pmcid: PMC10033671.
• Jain RK, Singh AM, Wang X, Guevara-Patiño JA, Sonpavde G. Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma. Expert Opin Emerg Drugs. 2023 Mar.28(1):17-26. Pubmedid: 36882977.
• Kwiatkowski AJ, Helm EY, Stewart J, Leon J, Drashansky T, Avram D, Keselowsky B. Design principles of microparticle size and immunomodulatory factor formulation dictate antigen-specific amelioration of multiple sclerosis in a mouse model. Biomaterials. 2023 Mar.294:122001. Pubmedid: 36716589.
• Kohlhapp FJ, O'Sullivan JA, Moore TV, Zloza A, Guevara-Patiño JA. NKG2D signaling shifts the balance of CD8 T cells from single cytokine- to polycytokine-producing effector cells. Mol Immunol. 2023 Mar.155:1-6. Pubmedid: 36634520. Pmcid: PMC9992161.
• Ward GA, Dalton RP, Meyer BS, McLemore AF, Aldrich AL, Lam NB, Onimus AH, Vincelette ND, Trinh TL, Chen X, Calescibetta AR, Christiansen SM, Hou HA, Johnson JO, Wright KL, Padron E, Eksioglu EA, List AF. Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes. Int J Mol Sci. 2023 Feb.24(4). Pubmedid: 36835307. Pmcid: PMC9966808.
• O'Sullivan JA, Kohlhapp FJ, Zloza A, Plaza-Rojas L, Burke B, Dulin NO, Guevara-Patiño JA. Memory Precursors and Short-Lived Effector T cell Subsets Have Different Sensitivities to TGFβ. Int J Mol Sci. 2023 Feb.24(4). Pubmedid: 36835342. Pmcid: PMC9966622.
• Medina E, Easa Y, Lester DK, Lau EK, Sprinzak D, Luca VC. Structure of the planar cell polarity cadherins Fat4 and Dachsous1. Nat Commun. 2023 Feb.14(1):891. Pubmedid: 36797229. Pmcid: PMC9935876.
• Lester DK, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, Adhikari E, Ming Q, Williamson DB, Frederick DT, Sharova T, White MG, Markowitz J, Cao B, Nguyen J, Johnson J, Beatty M, Mockabee-Macias A, Mercurio M, Watson G, Chen PL, McCarthy S, MoranSegura C, Messina J, Thomas KL, Darville L, Izumi V, Koomen JM, Pilon-Thomas SA, Ruffell B, Luca VC, Haltiwanger RS, Wang X, Wargo JA, Boland GM, Lau EK. Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy. Nat Cancer. 2023 Feb.4(2):222-239. Pubmedid: 36690875. Pmcid: PMC9970875.
• Jardim-Perassi BV, Irrera P, Lau JYC, Budzevich M, Whelan CJ, Abrahams D, Ruiz E, Ibrahim-Hashim A, Damgaci Erturk S, Longo DL, Pilon-Thomas SA, Gillies RJ. Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI. Contrast Media Mol Imaging. 2023 Jan.2023:1944970. Pubmedid: 36704211. Pmcid: PMC9836819.
• Dean JW, Helm EY, Fu Z, Xiong L, Sun N, Oliff KN, Muehlbauer M, Avram D, Zhou L. The aryl hydrocarbon receptor cell intrinsically promotes resident memory CD8+ T cell differentiation and function. Cell Rep. 2023 Jan.42(1):111963. Pubmedid: 36640340. Pmcid: PMC9940759.
• Conejo-Garcia JR, Biswas S, Chaurio R, Rodriguez PC. Neglected no more: B cell-mediated anti-tumor immunity. Semin Immunol. 2023 Jan.65:101707. Pubmedid: 36527759.
• Gonzalez-Perez D, Das S, Antfolk D, Ahsan HS, Medina E, Dundes CE, Jokhai RT, Egan ED, Blacklow SC, Loh KM, Rodriguez PC, Luca VC. Affinity-matured DLL4 ligands as broad-spectrum modulators of Notch signaling. Nat Chem Biol. 2023 Jan.19(1):9-17. Pubmedid: 36050494.
• Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, Innamarato P, Nagle L, Branthoover H, Wiener D, Schachner B, Martinez AJ, Richards AD, Rich CJ, Colón Colón M, Schell MJ, Teer JK, Khushalani NI, Weber JS, Mule JJ, Sondak VK, Pilon-Thomas S, Sarnaik AA. Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Clin Cancer Res. 2022 Dec.28(24):5317-5329. Pubmedid: 36215121.
• Gallen C, Dukes CW, Aldrich A, Macaisa L, Mo Q, Cubitt CL, Pilon-Thomas S, Giuliano AR, Czerniecki BJ, Costa RLB. Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study. Vaccines (Basel). 2022 Nov.10(11). Pubmedid: 36423026. Pmcid: PMC9696551.
• Lathia JD, Bayik D, Bartels CF, Lovrenert K, Watson DC, Zhang D, Kay K, Lee J, Lauko A, Johnson S, Lo A, Silver DJ, McGraw M, Grabowski MM, Mohammadi AM, Veglia F, Fan Y, Vogelbaum MA, Scacheri PC. Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets. Cancer Res. 2022 Nov.82(22):4274-4287. Pubmedid: 36126163. Pmcid: PMC9664137.
• Salvagno C, Mandula JK, Rodriguez PC, Cubillos-Ruiz JR. Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity. Trends Cancer. 2022 Nov.8(11):930-943. Pubmedid: 35817701. Pmcid: PMC9588488.
• Conejo-Garcia JR, Guevara-Patino JA. Barriers and Opportunities for CAR T-Cell Targeting of Solid Tumors. Immunol Invest. 2022 Nov.51(8):2215-2225. Pubmedid: 35797428. Pmcid: PMC9795814.
• Kwiatkowski AJ, Helm EY, Stewart JM, Drashansky TT, Cho JJ, Avram D, Keselowsky BG. Treatment with an antigen-specific dual microparticle system reverses advanced multiple sclerosis in mice. Proc Natl Acad Sci U S A. 2022 Oct.119(43):e2205417119. Pubmedid: 36256820. Pmcid: PMC9618088.
• Li J, Ruffell B. Cytokines drive prostate cancer lineage plasticity. Immunity. 2022 Oct.55(10):1761-1763. Pubmedid: 36223725.
• Mandula JK, Chang S, Mohamed E, Jimenez R, Sierra-Mondragon RA, Chang DC, Obermayer AN, Moran-Segura CM, Das S, Vazquez-Martinez JA, Prieto K, Chen A, Smalley KSM, Czerniecki B, Forsyth P, Koya RC, Ruffell B, Cubillos-Ruiz JR, Munn DH, Shaw TI, Conejo-Garcia JR, Rodriguez PC. Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses. Cancer Cell. 2022 Oct.40(10):1145-1160.e9. Pubmedid: 36150390. Pmcid: PMC9561067.
• Khamaisi B, Luca VC, Blacklow SC, Sprinzak D. Functional Comparison between Endogenous and Synthetic Notch Systems. ACS Synth Biol. 2022 Oct.11(10):3343-3353. Pubmedid: 36107643. Pmcid: PMC9594772.
• Hesterberg RS, Liu M, Elmarsafawi AG, Koomen JM, Welsh EA, Hesterberg SG, Ranatunga S, Yang C, Li W, Lawrence HR, Rodriguez PC, Berglund AE, Cleveland JL. TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate. Cancer Immunol Res. 2022 Oct.10(10):1263-1279. Pubmedid: 35969234. Pmcid: PMC9662872.
• Law V, Chen Z, Vena F, Smalley I, Macaulay R, Evernden BR, Tran N, Pina Y, Puskas J, Caceres G, Bayle S, Johnson J, Liu JKC, Etame A, Vogelbaum M, Rodriguez P, Duckett D, Czerniecki B, Chen A, Smalley KSM, Forsyth PA. A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neurooncol. 2022 Oct.24(10):1673-1686. Pubmedid: 35213727. Pmcid: PMC9527526.
• Celias DP, de Mingo Pulido Á, Ruffell B. Detection of exogenous DNA uptake by murine dendritic cells. STAR Protoc. 2022 Sep.3(3):101464. Pubmedid: 35719726. Pmcid: PMC9204794.
• Mullinax JE, Pilon-Thomas S. Adoptive Cell Therapy for Advanced Solid Tumors. Cancer J. 2022 Jul.28(4):255-256. Pubmedid: 35880933.
• Bustos X, Snedal S, Tordesillas L, Pelle E, Abate-Daga D. γδ T Cell-Based Adoptive Cell Therapies Against Solid Epithelial Tumors. Cancer J. 2022 Jul.28(4):270-277. Pubmedid: 35880936. Pmcid: PMC9335899.
• Alkhouli MA, Bazargan S, Pilon-Thomas S, Poch M, Chahoud J. Current State of Cell Therapies for Genitourinary Malignancies. Cancer J. 2022 Jul.28(4):294-300. Pubmedid: 35880939.
• Hensel J, Metts J, Gupta A, Ladle BH, Pilon-Thomas S, Mullinax J. Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy. Cancer J. 2022 Jul.28(4):322-327. Pubmedid: 35880942.
• Bekker RA, Zahid MU, Binning JM, Spring BQ, Hwu P, Pilon-Thomas S, Enderling H. Rethinking the immunotherapy numbers game. J Immunother Cancer. 2022 Jul.10(7). Pubmedid: 35793871. Pmcid: PMC9260835.
• Ming Q, Celias DP, Wu C, Cole AR, Singh S, Mason C, Dong S, Tran TH, Amarasinghe GK, Ruffell B, Luca VC. LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition. Nat Immunol. 2022 Jul.23(7):1031-1041. Pubmedid: 35761082.
• Daniel Grass G, Alfonso JCL, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Enderling H, Torres-Roca JF. The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 Jul.113(3):635-647. Pubmedid: 35289298. Pmcid: PMC9250625.
• Mandriani B, Pellè E, Mannavola F, Palazzo A, Marsano RM, Ingravallo G, Cazzato G, Ramello MC, Porta C, Strosberg J, Abate-Daga D, Cives M. Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors. J Immunother Cancer. 2022 Jun.10(6). Pubmedid: 35764366. Pmcid: PMC9240886.
• Wang X, Muzaffar J, Kirtane K, Song F, Johnson M, Schell MJ, Li J, Yoder SJ, Conejo-Garcia JR, Guevara-Patino JA, Bonomi M, Bhateja P, Rocco JW, Steuer CE, Saba NF, Chung CH. T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022 Jun.10(6). Pubmedid: 35676062. Pmcid: PMC9185557.
• Zhang T, Yin C, Fedorov A, Qiao L, Bao H, Beknazarov N, Wang S, Gautam A, Williams RM, Crawford JC, Peri S, Studitsky V, Beg AA, Thomas PG, Walkley C, Xu Y, Poptsova M, Herbert A, Balachandran S. ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis. Nature. 2022 Jun.606(7914):594-602. Pubmedid: 35614224. Pmcid: PMC9373927.
• Mandula JK, Rodriguez PC. Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells. Cancer Cell. 2022 Jun.40(6):597-599. Pubmedid: 35594864.
• Bekker RA, Kim S, Pilon-Thomas S, Enderling H. Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune system. Neoplasia. 2022 Jun.28:100796. Pubmedid: 35447601. Pmcid: PMC9043662.
• Chiappori AA, Creelan B, Tanvetyanon T, Gray JE, Haura EB, Thapa R, Barlow ML, Chen Z, Chen DT, Beg AA, Boyle TA, Castro J, Morgan L, Morris E, Aregay M, Hurtado FK, Manenti L, Antonia S. Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2022 Jun.28(11):2313-2320. Pubmedid: 35254415. Pmcid: PMC9167697.
• Cheng P, Chen X, Dalton R, Calescibetta A, So T, Gilvary D, Ward G, Smith V, Eckard S, Fox JA, Guenot J, Markowitz J, Cleveland JL, Wright KL, List AF, Wei S, Eksioglu EA. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma. Mol Ther. 2022 Jun.30(6):2315-2326. Pubmedid: 35150889. Pmcid: PMC9171150.
• Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, Nguyen J, Fan W, Cheng CH, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, Mulé J, Du D, Yoder SJ, Berglund A, Teer JK, Manley BJ. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2022 May.8(3):784-793. Pubmedid: 33994165.
• Creasy CA, Meng YJ, Forget MA, Karpinets T, Tomczak K, Stewart C, Torres-Cabala CA, Pilon-Thomas S, Sarnaik AA, Mule JJ, Garraway L, Bustos M, Zhang J, Patel SP, Diab A, Glitza IC, Yee C, Tawbi H, Wong MK, McQuade J, Hoon DSB, Davies MA, Hwu P, Amaria RN, Haymaker C, Beroukhim R, Bernatchez C. Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clin Cancer Res. 2022 May.28(9):1911-1924. Pubmedid: 35190823. Pmcid: PMC9064946.
• Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clin Cancer Res. 2022 May.28(10):2131-2146. Pubmedid: 35247927. Pmcid: PMC9106889.
• Song X, Chang S, Seminario-Vidal L, de Mingo Pulido A, Tordesillas L, Song X, Reed RA, Harkins A, Whiddon S, Nguyen JV, Moran Segura C, Zhang C, Yoder S, Sayegh Z, Zhao Y, Messina JL, Harro CM, Zhang X, Conejo-Garcia JR, Berglund AE, Sokol L, Zhang J, Rodriguez PC, Mule JJ, Futreal AP, Tsai KY, Chen PL. Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma. Cancer Discov. 2022 May.12(5):1294-1313. Pubmedid: 35247891. Pmcid: PMC9148441.
• Giuliano AR, Lancet JE, Pilon-Thomas S, Dong N, Jain AG, Tan E, Ball S, Tworoger SS, Siegel EM, Whiting J, Mo Q, Cubitt CL, Dukes CW, Hensel JA, Keenan RJ, Hwu P. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida. JAMA Oncol. 2022 May.8(5):748-754. Pubmedid: 35266953. Pmcid: PMC8914884.
• Chakraborty P, Parikh RY, Choi S, Tran D, Gooz M, Hedley ZT, Kim DS, Pytel D, Kang I, Nadig SN, Beeson GC, Ball L, Mehrotra M, Wang H, Berto S, Palanisamy V, Li H, Chatterjee S, Rodriguez PC, Maldonado EN, Diehl JA, Gangaraju VK, Mehrotra S. Carbon Monoxide Activates PERK-Regulated Autophagy to Induce Immunometabolic Reprogramming and Boost Antitumor T-cell Function. Cancer Res. 2022 May.82(10):1969-1990. Pubmedid: 35404405. Pmcid: PMC9117468.
• Anadon CM, Yu X, Hänggi K, Biswas S, Chaurio RA, Martin A, Payne KK, Mandal G, Innamarato P, Harro CM, Mine JA, Sprenger KB, Cortina C, Powers JJ, Costich TL, Perez BA, Gatenbee CD, Prabhakaran S, Marchion D, Heemskerk MHM, Curiel TJ, Anderson AR, Wenham RM, Rodriguez PC, Conejo-Garcia JR. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. 2022 May.40(5):545-557.e13. Pubmedid: 35427494. Pmcid: PMC9096229.